The information on this website is not intended for diagnosis or treatment. Please consult your physician for health concerns.

+90 850 321 50 00

VAP — Ventilator-Associated Pneumonia Prevention and Treatment Bundle

Prevention bundle, diagnostic criteria, and empirical treatment for pneumonia developing in patients on mechanical ventilation for more than 48 hours.

Written by: Saygı Hospital Health Guide Editorial Board
Published: · Last updated:

This content is for general information; please consult your physician for diagnosis and treatment.

References (2)

This content is for informational purposes only and does not constitute medical advice. You can book an appointment at our Göğüs Hastalıkları department. Book Appointment →

What is VAP — Ventilator-Associated Pneumonia Prevention and Treatment Bundle?

Ventilator-Associated Pneumonia (VAP) is a nosocomial pneumonia developing ≥48 hours after endotracheal intubation. It occurs in 9-27% of mechanically ventilated patients, mortality is 20-50%, and it prolongs hospitalization by 7-10 days and costs by 40 000-80 000 USD.

Pathogenesis — oropharyngeal colonization (biofilm on the endotracheal tube), microaspiration (subglottic secretions), gastric colonization (increased by PPI stress-ulcer prophylaxis), and environmental pathogens (water sources, contaminated equipment). Ventilator-patient asynchrony and altered consciousness increase the risk.

Diagnosis — clinical suspicion (new/progressive infiltrate + fever/leukocytosis + purulent secretions) plus microbiological confirmation (endotracheal aspirate 10⁵ CFU/mL, BAL 10⁴ CFU/mL, protected specimen brush 10³ CFU/mL). CPIS (Clinical Pulmonary Infection Score) >6 is a useful supportive tool.

Empirical therapy (IDSA/ATS 2016, Turkish Thoracic Society 2021) is stratified by risk — early-onset VAP (<5 days, no MDR risk): narrow spectrum; late-onset or high MDR risk (hospital stay >5 days, prior antibiotic use, high local resistance): dual gram-negative coverage plus MRSA coverage.

Symptoms

New or progressive lung infiltrate appearing >48 hours after initiating mechanical ventilation
Systemic infection signs — fever >38 or hypothermia <36, leukocytes >12 000 or <4000
Pulmonary symptoms — increasing secretions, purulent tracheal aspirate, rising FiO2/PEEP requirement, worsening oxygenation
CPIS components — fever, leukocyte count, tracheal secretions, PaO2/FiO2, chest X-ray infiltrate, tracheal culture
New-onset or worsening ARDS and other organ dysfunction — may progress to MOF

Risk Factors

Prolonged mechanical ventilation (>7 days), reintubation, tracheostomy, low GCS, neurological disease
Antibiotic exposure, high use of PPI or H2-blockers, supine position
Altered consciousness, severe neurological disease, bulbar dysfunction (reduced cough reflex)
MDR risk factors — antibiotic use in the last 90 days, hospital stay >5 days, hemodialysis, immunosuppression, high local resistance
ETT cuff pressure <20 cmH2O or accumulation of subglottic secretions

When to See a Doctor?

If you experience any of the following symptoms, seek medical attention promptly:

  • In every mechanically ventilated patient — implement the VAP prevention bundle from day 1
  • Clinical suspicion (fever, new infiltrate, purulent secretions) — rapid microbiological evaluation and empirical antibiotics
  • CPIS >6 + clinical deterioration — de-escalate based on microbiology results

Treatment Methods

01
VAP Prevention Bundle (IHI 5-component): head-of-bed elevation 30-45°, daily sedation interruption (SAT) + SBT assessment, DVT prophylaxis (LMWH), selective stress-ulcer prophylaxis (PPI in high-risk patients; sucralfate in low-risk), daily oral hygiene with chlorhexidine
02
Additional measures — ETT with subglottic-secretion drainage, cuff-pressure monitoring (20-30 cmH2O), closed suction system, early tracheostomy (>10-14 days), regular body-position changes
03
On clinical suspicion — endotracheal aspirate + culture (quantitative ideal), 2 sets of blood cultures, CRP/procalcitonin, trend in SOFA, CPIS score
04
Empirical therapy — early VAP (<5 days, no MDR risk): ceftriaxone 2 g IV + levofloxacin 750 mg IV or ampicillin-sulbactam 3 g IV. Late VAP (>5 days or MDR risk): piperacillin-tazobactam 4.5 g IV + vancomycin 15 mg/kg IV ± aminoglycoside (amikacin), or meropenem 1 g IV + vancomycin
05
De-escalation — at 48-72 hours, narrow spectrum based on cultures; treatment 7-8 days (except S. aureus, Pseudomonas) or 10-14 days (MRSA, Pseudomonas, complicated)
06
Treatment response — CPIS should fall within 48-72 hours, fever should resolve within 5 days, oxygenation should improve; if no response, reassess (source control, resistance, complications: empyema, abscess)

Which Department to Visit?

You can visit our Göğüs Hastalıkları department for these complaints. Our specialist physicians will create the most suitable treatment plan for you.

Learn About Göğüs Hastalıkları Department

Let us help you

You can make an appointment with our specialists or contact us for your concerns.

Book AppointmentContact Us

Related Health Topics

Other articles from the same department you may want to explore.

Asthma

Göğüs Hastalıkları

Asthma is characterized by wheezing, coughing and shortness of breath attacks; with proper treatment it can be kept under control.

COPD (Chronic Obstructive Pulmonary Disease)

Göğüs Hastalıkları

COPD is an irreversible lung disease characterized by shortness of breath and chronic cough; quitting smoking slows its progression.

Pneumonia

Göğüs Hastalıkları

Pneumonia presents with high fever, cough and shortness of breath; the vast majority recover with appropriate antibiotic treatment.

Tuberculosis (TB)

Göğüs Hastalıkları

Tuberculosis presents with weeks-to-months of cough, fever, and night sweats; early diagnosis and treatment lead to full recovery.

Pleural Effusion

Göğüs Hastalıkları

Pleural effusion is the accumulation of excess fluid in the pleural space, resulting from imbalances in fluid production and removal, and represents a manifestation of diverse cardiopulmonary, infectious, and malignant disorders.

Pneumothorax

Göğüs Hastalıkları

Pneumothorax is the presence of air in the pleural space resulting in partial or complete lung collapse, classified as spontaneous (primary/secondary), traumatic, or iatrogenic, with tension pneumothorax representing a life-threatening emergency.

Bronchitis (Acute and Chronic)

Göğüs Hastalıkları

Acute bronchitis is mostly viral and resolves spontaneously, while chronic bronchitis is a smoking-related component of COPD.

Bronchiectasis

Göğüs Hastalıkları

Bronchiectasis is a chronic respiratory disease characterized by permanent, abnormal dilation of bronchi with associated destruction of muscular and elastic components of airway walls, resulting in impaired mucociliary clearance and recurrent infection.

Health Disclaimer: The information on this page is prepared for general informational purposes only. It does not replace medical diagnosis and treatment. Please consult your physician for your complaints. Saygı Hospital does not accept responsibility for actions taken based on the information on this page.